Anavex announces upcoming presentation of data from ATTENTION-AD study

Anavex (AVXL) Life Sciences announced its upcoming presentation of topline long-term data from the Phase IIb/III ATTENTION-AD Open-Label-Extension, OLE, trial at the J.P. Morgan 2025 Healthcare Conference, taking place January 13-16, 2025, in San Francisco, CA. The presentation will highlight new findings from the ATTENTION-AD study evaluating potential benefit of oral once daily blarcamesine in early Alzheimer’s disease. The data reflect up to 144 weeks of continuous treatment in the OLE phase, following the prior 48-week double-blind Phase IIb/III study, for a total of up to 192 weeks of safety and efficacy data.